These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24302284)

  • 21. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The structural error-in-equation model to evaluate individual bioequivalence.
    Carrasco JL; Jover L
    Biom J; 2005 Oct; 47(5):623-34. PubMed ID: 16385903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residuals and outliers in replicate design crossover studies.
    Schall R; Endrenyi L; Ring A
    J Biopharm Stat; 2010 Jul; 20(4):835-49. PubMed ID: 20496209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new approach for outliers in a bioavailability/bioequivalence study.
    Liao JJ
    J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
    Zintzaras E; Bouka P
    Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Application of multilevel models in the evaluation of bioequivalence (II).].
    Liu QL; Shen ZZ; Li XS; Chen F; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Mar; 31(3):333-9. PubMed ID: 20510066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
    Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
    Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method.
    Shen M; Machado SG
    J Biopharm Stat; 2017; 27(2):257-264. PubMed ID: 27906608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions.
    Almeida S; Filipe A; Neves R; Desjardins I; Shink E; Castillo A
    Arzneimittelforschung; 2010; 60(3):116-23. PubMed ID: 20422942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations.
    Joukhadar C; Schenk B; Kaehler ST; Kollenz CJ; Bauer P; Müller M; Eichler HG
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):631-6. PubMed ID: 14564429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing bioequivalence in serial sacrifice designs.
    Wolfsegger MJ
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):103-13. PubMed ID: 17053981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and analysis of intra-subject variability in cross-over experiments.
    Chinchilli VM; Esinhart JD
    Stat Med; 1996 Aug; 15(15):1619-34. PubMed ID: 8858786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The existence of sequence effect in cross-over bioequivalence trials.
    Zintzaras E
    Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):241-4. PubMed ID: 11420897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical aspects of bioequivalence testing between two medicinal products.
    Zintzaras E
    Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.